How Long Can You Live with Colon Cancer Without Treatment?

Survival without treatment for colon cancer varies enormously depending on how advanced the disease is at diagnosis, but the numbers are sobering. For advanced or incurable disease, older research puts average survival at roughly ten months from diagnosis, while a more recent study of untreated advanced cases found a median survival of about 24 months. Early-stage cancers left untreated can take years to become fatal, but they almost always do. The range is wide enough that no single number captures the reality, and the factors that push someone toward the shorter or longer end of that range are worth understanding in detail.

Survival Timelines From the Available Evidence

Pinning down how long someone lives with untreated colon cancer is tricky because researchers rarely study it intentionally. Ethical guidelines prevent randomizing patients to a “no treatment” group. Instead, the data comes from patients who refused treatment, were too frail for surgery, or were diagnosed in an era when less was available. Each of these groups tells a somewhat different story.

One of the earliest large-scale reviews, covering 583 patients with colon or rectal cancer who received no curative treatment, found an average survival from diagnosis of incurable disease to death of 9.8 months.¹ That figure, though, lumps together patients at various stages and skews toward people with disease that was already considered incurable at the time it was found.

A more recent study focusing specifically on untreated advanced colorectal cancer patients reported a median survival of 24 months, with individual cases ranging from 16 to 42 months.² Meanwhile, a study of elderly patients who did not undergo curative surgery found a median life expectancy of about 586 days, or roughly 19 months, with the full range stretching from as few as 105 days to nearly five years.³

The gap between the oldest and newest data reflects improvements in supportive care, earlier detection, and better management of symptoms and complications. Someone diagnosed today who declines treatment will likely survive longer than someone diagnosed decades ago, even without any cancer-directed therapy, simply because everything around the cancer is managed better now.

How Stage at Diagnosis Changes the Picture

Stage is the single most powerful predictor of how long untreated colon cancer takes to become fatal. A large analysis of patients who refused surgery found dramatic differences by stage. For stage I disease, patients who refused surgery still had a median survival of about 0.9 years. Stage II refusers survived a median of about 0.7 years, and stage III refusers about 0.5 years. Compare that with patients who accepted surgery: median survival was 9.9 years for stage I, 7.8 years for stage II, and 6.6 years for stage III.⁴ The difference is not subtle. It is measured in years of life.

A separate study looking at the same question found that patients who refused surgery had a five-year survival of about 55% and a median survival of roughly 66 months, compared to 66% five-year survival and about 82 months median survival for those who had surgery.⁵ These numbers are notably more optimistic than the first study, likely because this cohort included a higher proportion of early-stage cancers. That discrepancy illustrates the point: the “survival without treatment” question has no single answer. Stage composition of the group under study changes the numbers drastically.

For patients who also refused chemotherapy for stage III disease specifically, one study found a median survival of about 3.35 years, compared to 8.46 years for those who accepted it. Five-year survival dropped from 64% with chemotherapy to 38% without it.⁴ Chemotherapy clearly adds time even for people who do not have surgery, though the benefit is smaller than what surgery provides.

How Fast Colon Tumors Grow

Understanding the natural pace of tumor growth helps explain why some people live years with untreated disease while others decline within months. Colon cancers do not all grow at the same speed. A retrospective study measuring tumor changes over time found a median volume doubling time of about 211 days for primary colon and rectal tumors, meaning the average tumor roughly doubled in size every seven months.⁶ Another imaging study found volume doubling times ranging from as little as 18 days to more than seven years, with a median of about 0.7 years.⁷ That enormous spread means some tumors are almost indolent, barely changing over years, while others are aggressive enough to double in weeks.

Metastatic deposits tend to grow faster than the original tumor. Serial CT scans of patients with colorectal metastases showed doubling times of 50 to 95 days for liver, lymph node, and peritoneal metastases.⁸ Once the cancer has spread, the clock speeds up considerably.

Molecular Subtypes and Why They Matter

Not all colon cancers are genetically alike, and certain mutations predict a much shorter survival even with treatment. The most notorious is BRAF V600E, found in roughly one in ten colorectal cancer patients. Tumors carrying this mutation have a median survival of less than 12 months in the advanced setting.⁹ A large meta-analysis confirmed that BRAF mutations are associated with worse overall survival, and KRAS mutations carry a similar, though somewhat smaller, penalty.¹⁰

The picture gets more complicated when you factor in microsatellite instability. Tumors that are microsatellite-unstable sometimes respond differently to the immune system. A pooled analysis of several trials found that among microsatellite-stable tumors, BRAF and KRAS mutations were both linked to significantly worse time to recurrence and overall survival. But in microsatellite-unstable tumors, the time to recurrence did not differ significantly by mutation status, though survival after relapse was still shorter for patients with those mutations.¹¹ These distinctions are relevant because they help explain why two patients with seemingly identical tumors by appearance can have very different outcomes.

Where the Tumor Sits in the Colon

Left-sided and right-sided colon cancers are, in many respects, different diseases. They develop through somewhat different genetic pathways, tend to present at different stages, and carry different prognoses. A SEER-based analysis found a median survival of 78 months for right-sided colon cancers versus 89 months for left-sided cancers. At five years, survival was about 56% for right-sided tumors and 60% for left-sided ones.¹² A European study found similar patterns, with a five-year relative survival of about 66% for right-sided versus 68% for left-sided tumors overall, and a sharper gap in advanced disease: roughly 13% five-year survival for right-sided stage IV disease compared to about 20% for left-sided stage IV.¹³

The relationship flips in very early disease, though. Some data suggests that in stage I and II cancers, right-sided tumors actually carry a slightly better prognosis than left-sided ones.¹⁴ The practical takeaway for someone facing an untreated right-sided colon cancer is that it may behave more aggressively in later stages than a left-sided tumor would.

The Complications That Can Cut Survival Short

Without treatment, colon cancer does not simply grow quietly until it claims your life. It creates emergencies along the way. The most common is bowel obstruction. Roughly 10% to 18% of colon cancer patients present with obstruction at diagnosis, and colorectal cancer is responsible for over 60% of all large bowel obstructions.¹⁵¹⁶ Complete obstruction dramatically changes the trajectory. An older but still-cited surgical series found that five-year cancer-specific survival was about 59% for patients who presented without obstruction but only about 32% for those with complete obstruction, because obstructing tumors tend to be more advanced and more aggressive.¹⁷

Perforation is rarer but more dangerous. The prevalence of perforation in colorectal cancer patients is estimated at 3% to 10%. Patients whose tumors perforate the bowel wall have much higher complication rates and, critically, a significantly lower three-year recurrence-free survival even after surgery.¹⁸ For someone without treatment, a perforation can cause peritonitis, sepsis, and death within days if emergency surgery is not performed.

These complications explain why the real-world trajectory of untreated colon cancer is not a smooth decline. It often involves a crisis point, an obstruction or perforation, that forces a decision about emergency intervention even in patients who had previously chosen not to pursue treatment.

What Ultimately Causes Death

The liver is the most common site for colon cancer to spread, and liver failure from metastatic disease is a leading cause of death. An autopsy-based study found that about 62% of colorectal cancer patients who died had liver metastases, and in just over half of those cases the liver metastases directly contributed to the death.¹⁹ In about 38% of patients, though, metastatic disease at death did not involve the liver at all, meaning the cancer had spread to the lungs, peritoneum, or other sites and caused death through different mechanisms.

For untreated patients, even palliative surgery to remove the primary tumor without attempting to cure the disease appears to extend survival. One study found a median survival of about 544 days with palliative resection versus 233 days without any surgery at all.²⁰ Removing the primary tumor reduces the risk of obstruction, perforation, and bleeding, even when it cannot address the disease that has already spread elsewhere.

How Quality of Life Deteriorates

Survival time is one measure, but what that time feels like matters just as much to people making treatment decisions. Research tracking health-related quality of life in patients with advanced cancer found that overall quality of life began declining significantly in the last nine months of life, with the steepest drop in the final three months. Fatigue, pain, appetite loss, shortness of breath, constipation, and nausea all worsened significantly in the final year.²¹ This trajectory applies broadly to advanced cancers, not just colon cancer, but the symptom profile, particularly the constipation, obstruction risk, and pain from abdominal disease, is especially relevant for untreated colon cancer.

For people who forgo treatment, the earlier months may feel relatively normal, particularly if the cancer is still localized. Pain and functional decline tend to accelerate later. This creates what some patients describe as a honeymoon period that can be misleading: feeling well initially reinforces the belief that treatment is unnecessary, until symptoms escalate rapidly and the window for effective intervention has narrowed or closed.

Why People Refuse Treatment

Understanding who declines treatment and why is relevant to the broader question, because these patients make up the main population from which “untreated survival” data is drawn. A systematic review of treatment refusal in colorectal cancer identified several consistent predictors: older age, being female, being unmarried, having more coexisting health problems, and lacking health insurance were all associated with higher rates of refusal.²² These are not random cross-sections of cancer patients. They tend to be sicker, older, and more socially isolated, which means the survival data from treatment refusers may actually underestimate how long a younger, otherwise healthy person might live without treatment.

Among patients who specifically refused chemotherapy for stage III disease, about 22% of those who declined cited concerns about toxicity and side effects as their primary reason.²³ Fear of side effects is not an irrational concern, chemotherapy does carry real risks, but the survival data suggests that for most patients the trade-off strongly favors treatment. Frail elderly patients are a genuine exception, as they benefit less from surgery and face higher surgical risks.²⁴

Alternative Medicine and Survival

Some people who refuse conventional treatment turn to alternative therapies instead, and the data on this is blunt. A study using the National Cancer Database found that colorectal cancer patients who chose alternative medicine in place of conventional treatment had a five-year survival of about 33%, compared to roughly 79% for those who received standard treatment.²⁵ A separate analysis found that using complementary medicine was independently associated with a greater risk of death from colorectal cancer, with an adjusted hazard ratio of about 2.6, largely because complementary medicine use was linked to higher rates of refusing or delaying conventional treatments like surgery and chemotherapy.²⁶

The distinction between alternative and complementary is worth noting here. Using herbal supplements or acupuncture alongside conventional treatment is complementary use. Using them instead of surgery or chemotherapy is alternative use. The survival penalty comes overwhelmingly from the “instead of” group. Complementary use that does not delay or replace standard care appears to carry a much smaller, though possibly still real, risk.

Can Colon Cancer Ever Disappear on Its Own

Spontaneous regression of colon cancer, where the tumor shrinks or vanishes without treatment, has been documented, but it is extraordinarily rare. A review of all reported cases from 1900 to 2005 found only a handful of confirmed instances across more than a century of medical literature.²⁷ A 2025 case report described a 70-year-old woman whose primary ascending colon tumor completely regressed on repeated endoscopic exams, though a regional lymph node metastasis persisted. The regressed tumor showed signs of a strong immune response, with heavy infiltration of immune cells, and the cancer was found to have high microsatellite instability, a feature known to make tumors more visible to the immune system.²⁸

These cases are scientifically fascinating but not something anyone should count on. The probability of spontaneous regression is so low that no credible source estimates it at anything more than a fraction of a percent. What these cases do illuminate is the role the immune system can play, which is part of why immunotherapy has become a major treatment option for the subset of colon cancers with high microsatellite instability. The biology that occasionally allows spontaneous regression in rare individuals has been harnessed therapeutically for a broader group of patients.